| Online-Ressource |
Verfasst von: | Grauer, Oliver Martin [VerfasserIn]  |
| Pascher, Christina [VerfasserIn]  |
| Hartmann, Christian [VerfasserIn]  |
| Zeman, Florian [VerfasserIn]  |
| Weller, Michael [VerfasserIn]  |
| Proescholdt, Martin [VerfasserIn]  |
| Brawanski, Alexander [VerfasserIn]  |
| Pietsch, Thorsten [VerfasserIn]  |
| Wick, Wolfgang [VerfasserIn]  |
| Bogdahn, Ulrich [VerfasserIn]  |
| Hau, Peter [VerfasserIn]  |
Titel: | Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas |
Titelzusatz: | a prospective single-arm monocentric phase-II study (RNOP-05) |
Verf.angabe: | Oliver Grauer, Christina Pascher, Christian Hartmann, Florian Zeman, Michael Weller, Martin Proescholdt, Alexander Brawanski, Thorsten Pietsch, Wolfgang Wick, Ulrich Bogdahn, Peter Hau |
E-Jahr: | 2011 |
Jahr: | 4 March 2011 |
Umfang: | 9 S. |
Fussnoten: | Gesehen am 11.07.2022 |
Titel Quelle: | Enthalten in: Journal of neuro-oncology |
Ort Quelle: | Dordrecht [u.a.] : Springer Science + Business Media B.V, 1983 |
Jahr Quelle: | 2011 |
Band/Heft Quelle: | 104(2011), 3, Seite 801-809 |
ISSN Quelle: | 1573-7373 |
Abstract: | The objective of this prospective, monocentric phase-II pilot study was to evaluate toxicity and efficacy of neoadjuvant temozolomide (TMZ) and 13-cis retinoic acid (13-cRA) treatment in patients with newly diagnosed anaplastic gliomas after total or subtotal tumor resection. The primary endpoint of the study was median progression-free survival (PFS). Secondary endpoints were toxicity and PFS rates at 6, 12 and 24 months. Thirty-two adult patients were included in the study and treated with a median number of 10 TMZ and 13-cRA cycles (range 1-26). The majority of patients had favorable prognostic factors characterized by young age, complete resection, oligodendroglial histology, 1p/19q co-deletion, O6-methylguanine-DNA methyltransferase (MGMT) promotor methylation and isocitrate dehydrogenase 1 (IDH1) mutation. Grade 3/4 myelotoxicity occurred in 5/32 patients, and about 90% of patients suffered from grade 2/3 adverse events attributable to 13-cRA. The median PFS was 37.8 months (95% CI 22.2-53.4). The 6-, 12- and 24-month PFS rates were 84.4, 75 and 42.4%. The extent of tumor resection was the only prognostic factor associated with better PFS. TMZ and 13-cRA treatment did not improve PFS when retrospectively compared to the TMZ-treated group within the randomized NOA-04 phase-III trial. In conclusion, 13-cRA addition to TMZ in a neoadjuvant setting showed acceptable toxicity, but did not yield an advantage in PFS in patients with newly diagnosed anaplastic gliomas after total or subtotal tumor resection. |
DOI: | doi:10.1007/s11060-011-0548-y |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1007/s11060-011-0548-y |
| Volltext: https://link.springer.com/article/10.1007/s11060-011-0548-y |
| DOI: https://doi.org/10.1007/s11060-011-0548-y |
Datenträger: | Online-Ressource |
Sprache: | eng |
Bibliogr. Hinweis: | Errata: Grauer, Oliver Martin, 1969 - : Erratum to |
Sach-SW: | 13-cis retinoic acid |
| 1p/19q co-deletion |
| Anaplastic glioma |
| IDH1 |
| MGMT |
| Temozolomide |
K10plus-PPN: | 1809699614 |
Verknüpfungen: | → Zeitschrift |
Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas / Grauer, Oliver Martin [VerfasserIn]; 4 March 2011 (Online-Ressource)